Weight Loss
SURMOUNT-2: Tirzepatide confers up to 15.7% weight loss for adults with obesity, diabetes
Adults with overweight or obesity and type 2 diabetes achieved a mean weight loss of more than 13% after taking either 10 mg or 15 mg of tirzepatide for 72 weeks, according to topline results from the SURMOUNT-2 trial.
Weight loss in older healthy adults associated with increased mortality risk
Weight loss of 5% or greater was associated with an increased risk for all-cause mortality among older healthy adults, particularly men, highlighting the importance of monitoring these patients for weight changes, according to researchers.
Weight regain does not erode cardiometabolic benefits of weight-loss programs
Participants in behavioral weight-loss programs improved several CV risk factors for at least 5 years after an intervention ended, despite weight regain, compared with low-intensity programs or controls, researchers reported.
GLP-1/glucagon dual agonist linked to 10% weight loss in half of adults with obesity
About half of adults taking a novel peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity in nonalcoholic steatohepatitis lost 10% or more body weight at 24 weeks, according to a press release.
Sleep quality may affect adherence to exercise, diet goals in those trying to lose weight
Improved domains of sleep quality may improve patients’ ability to adhere to components of a behavioral weight-loss intervention, including exercise and diet goals, a speaker reported.
Ozempic for rapid weight loss may result in facial sagging, drooping
Taking Ozempic may result in a side effect coined the “Ozempic face drop,” according to Konstantin Vasyukevich, MD, a private facial plastic surgeon in New York.
People with NAFLD who exercise are 3.5 times more likely to achieve liver fat reduction
Physically active patients with nonalcoholic fatty liver disease were more likely to achieve at least a 30% reduction in MRI-measured liver fat, according to research in The American Journal of Gastroenterology.
Once-weekly semaglutide improves eating control behaviors among adults with obesity
Once-weekly semaglutide 2.4 mg is associated with reductions in hunger and improved fullness at 20 weeks as well as improved craving control at 2 years, according to findings from the STEP 5 randomized controlled trial.
Phenotyping, genetics hold keys to precision medicine in obesity treatment
From bariatric surgery to lifestyle interventions to medications, there are several options available for treating obesity. However, determining the treatment plan that works best for each person remains a challenge.
Does time-restricted eating confer clinically significant health benefits for adults?
There are many benefits of time-restricted eating and many mechanisms that may play a role. It has been shown that time-restricted eating affects the gut microbiome. When we restrict our eating window to only a certain period during the day, it increases the diversity of the gut microbiome and also affects the composition. We know that our gut microbiome may affect our insulin sensitivity and our immune function, and it may have beneficial effects on our cardiovascular system.